Modulation of cellular radiation responses by histone deacetylase inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Histone deacetylase (HDAC) inhibitors represent a novel class of targeted cancer chemotherapeutics.
• Clinical trials show promising anticancer effects of HDAC inhibitors in hematologic and solid cancers at well-tolerated doses.
• HDAC inhibitors are known to induce cell-cycle arrest, differentiation, and apoptosis, but their precise mechanisms vary across different cellular contexts.

Purpose of the Study:

• To review the cellular effects of HDAC inhibitors.
• To discuss the interaction of HDAC inhibitors with other anticancer agents.
• To focus on the mechanisms by which HDAC inhibitors enhance cancer cell sensitivity to ionizing radiation.

Main Methods:

• Literature review of recent studies on HDAC inhibitors.
• Analysis of mechanisms underlying HDAC inhibitor effects on cancer cells.
• Examination of the synergistic effects of HDAC inhibitors with other cytotoxic modalities.

Main Results:

• HDAC inhibitors demonstrate intrinsic anticancer properties, including cell-cycle arrest and apoptosis induction.
• These inhibitors modulate cellular responses to various cytotoxic agents like radiation and chemotherapy.
• Growing evidence suggests potential clinical utility of HDAC inhibitors in combination therapies.

Conclusions:

• HDAC inhibitors are a promising class of anticancer agents with diverse mechanisms of action.
• Their ability to sensitize cancer cells to radiation therapy is of significant clinical interest.
• Combination strategies involving HDAC inhibitors and conventional therapies warrant further investigation.